AngioDynamics (NASDAQ:ANGO) Releases FY 2026 Earnings Guidance

AngioDynamics (NASDAQ:ANGO - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of -0.350--0.250 for the period, compared to the consensus earnings per share estimate of -0.227. The company issued revenue guidance of $305.0 million-$310.0 million, compared to the consensus revenue estimate of $304.9 million.

AngioDynamics Stock Down 1.5%

NASDAQ ANGO traded down $0.13 on Friday, reaching $8.61. The company had a trading volume of 258,633 shares, compared to its average volume of 657,946. The stock has a market capitalization of $349.65 million, a P/E ratio of -10.37 and a beta of 0.60. The company's fifty day moving average is $9.88 and its 200 day moving average is $10.07. AngioDynamics has a 52-week low of $5.83 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. The business had revenue of $80.16 million during the quarter, compared to analyst estimates of $74.26 million. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. AngioDynamics's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.06) EPS. On average, research analysts expect that AngioDynamics will post -0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ANGO. Canaccord Genuity Group set a $17.00 price objective on AngioDynamics and gave the company a "buy" rating in a research note on Wednesday. Lake Street Capital began coverage on AngioDynamics in a research note on Wednesday. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of AngioDynamics in a research note on Wednesday.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AngioDynamics stock. Goldman Sachs Group Inc. boosted its stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 9.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 259,226 shares of the medical instruments supplier's stock after purchasing an additional 22,658 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.64% of AngioDynamics worth $2,434,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 89.43% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.